Plaque Reversal With Early, Aggressive Lipid Lowering Therapy (EAGLE)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Status: Enrolling

Conditions: Coronary Artery Disease Progression

Study type: Observational

Funder types: Other

Identifiers

NCT05783804

NL75337.018.20

Details and patient eligibility

About

This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with heterozygous familial hypercholesterolemia
• Adult between 18 and 50 years old
• LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion

Exclusion criteria

• Renal insufficiency, defined as eGFR < 30 ml/min
• History of atherosclerotic cardiovascular events
• Atrial fibrillation
• Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
• Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.